The Effects of 6-Month Hydrogen-Rich Water Intake on Molecular and Phenotypic Biomarkers of Aging in Older Adults Aged 70 Years and Over

Executive summary

This is the study most likely to be cited on a hydrogen water generator product page, and it is worth reading in full because what it found is narrower than how it is usually presented.

Forty older adults, twenty of them women, were randomly allocated in a parallel-group design to receive either 0.5 litres per day of hydrogen-rich water containing 15 ppm of hydrogen, or a control drink containing 0 ppm, over a six-month intervention. Mean age was 76.0 ± 5.6 years.

A wide range of biomarkers was assessed at baseline and at six months: molecular markers in blood covering DNA and chromosomes, nutrient sensing, protein and lipid metabolism, oxidative stress and mitochondria, cell senescence and inflammation, plus brain metabolism, cognitive functioning, physical function, body composition, resting blood pressure, facial skin features, sleep outcomes and health-related quality of life.

A significant treatment-by-time interaction was found for telomere length (P = 0.049) and for TET2 expression, a marker of DNA methylation (P = 0.040). A strong trend was reported for degree of DNA methylation at P = 0.166 - which is not statistically significant, and the authors describe it as a trend rather than a finding. Hydrogen-rich water was superior for several brain metabolite measures (P < 0.05) and for chair stand performance (P = 0.01).

Crucially: no significant differences were found between interventions for the other outcomes (P > 0.05). Most of what was measured did not move.

Why this research matters

Anyone buying a hydrogen water generator is implicitly relying on evidence like this. It is the most relevant randomised trial available, and it is a pilot.

It is also a useful lesson in reading trial reports. Two significant P values close to the 0.05 threshold, among a very large number of measured outcomes, is a weaker result than a headline suggests - and the honest study reports the null findings alongside them, as this one does.

What the researchers found

Telomere length. Significant treatment-by-time interaction (P = 0.049). Length increased after hydrogen-rich water, from 0.99 ± 0.15 at baseline to 1.02 ± 0.26 at follow-up, and decreased after control water, from 0.92 ± 0.27 to 0.79 ± 0.15.

TET2 expression (a DNA methylation marker). Increased in both groups, but the degree of elevation was significantly greater with hydrogen-rich water (from 0.81 ± 0.52 to 1.62 ± 0.66) than with control water (from 1.13 ± 0.82 to 1.76 ± 0.87), P = 0.040.

Degree of DNA methylation. A strong trend only, P = 0.166 - not statistically significant. Methylation increased in the hydrogen group (120.6 ± 39.8 ng to 126.6 ± 33.8 ng) and decreased in the control group (133.6 ± 52.9 ng to 121.2 ± 38.4 ng).

Brain metabolites. Hydrogen-rich water was superior for choline and NAA in the left frontal grey matter, creatine in the right parietal white matter, and NAA in the right parietal mesial grey matter (P < 0.05).

Physical function. Significantly improved chair stand performance versus control (P = 0.01).

All other outcomes. No significant differences between interventions (P > 0.05).

What the results mean

A handful of biomarkers moved and most measured outcomes did not. That is the accurate summary.

The telomere finding is the one most often quoted, and it needs care. P = 0.049 sits fractionally below the conventional 0.05 threshold, in a pilot trial of 40 people, across a very large number of measured outcomes. With that many comparisons, one or two results at that level would be expected by chance.

The chair stand result is arguably the most interesting, because it is a functional measure rather than a molecular one - older adults standing up from a chair more easily is a real-world outcome. It is still a single measure in a pilot trial.

What is reasonably supported: hydrogen-rich water at this dose over six months was associated with changes in a small number of biomarkers in older adults, and warrants a larger trial. What is not supported: any claim about anti-ageing, longevity, or health outcomes.

Strengths and limitations

Strengths

• Randomised parallel-group design with a matched 0 ppm control drink.
• Six-month duration, long for this field.
• Pre-registered at ClinicalTrials.gov (NCT04430803).
• Specified hydrogen concentration (15 ppm) and dose (0.5 L per day), which many studies in this area do not.
• Balanced sex distribution, with 20 women among 40 participants.
• Reports null results explicitly alongside the significant ones.
• Combines molecular, brain-imaging and functional outcomes.

Limitations

• Small sample of 40 participants; explicitly described as a pilot trial.
• Very large number of outcomes measured, raising the chance of spurious significant results.
• Two key P values sit close to the 0.05 threshold.
• Blinding procedures not reported in the source abstract.
• Narrow age range limits generalisability.
• Biomarker endpoints rather than health outcomes.
• No replication published as far as we are aware.

Evidence in context

This sits within a field that its own reviewers describe as unresolved. A 2023 review counted 81 clinical trials and 64 human-study publications and closed by asking whether hydrogen gas will become a drug substance in future practice.

A 2021 review of hydrogen gas therapy covers preclinical work and clinical trials largely in acute medical settings - ischaemia-reperfusion injury, organ preservation - which is a different context again.

No larger randomised trial has replicated these biomarker findings as far as we are aware. The evidence quality on this specific question has not improved since 2021.

Related research

1. Molecular hydrogen therapy - a review on clinical studies and outcomes Johnsen HM, Hiorth M, Klaveness J. Molecules 28(23):7785. 2023. PMID 38067515; PMC10707987; doi:10.3390/molecules28237785.The broad review of human hydrogen studies that places this trial in context.
2. Hydrogen gas therapy: from preclinical studies to clinical trials Sano M, Tamura T. Current Pharmaceutical Design 27(5):650-658. 2021. PMID 33349213; doi:10.2174/1381612826666201221150857.Covers hydrogen gas therapy by inhalation in acute clinical settings - a different route and population.
3. General wellness: policy for low risk devices - guidance for industry and FDA staff U.S. FDA, Center for Devices and Radiological Health. Docket FDA-2014-N-1039. 2019. CDRH guidance.FDA guidance on general wellness claims versus disease claims.
4. Health products compliance guidance U.S. Federal Trade Commission, Bureau of Consumer Protection. 2022. Replaces the 1998 Dietary Supplements advertising guide.FTC substantiation standard, relevant to how pilot-trial findings may be advertised.